Skip to main content

Blake Moses, PhD

Academic Title:

Post Doc Fellow

Primary Appointment:

Center for Stem Cell Biology and Regenerative Medicine


20 Penn St. Baltimore, MD 21201

Phone (Primary):


Education and Training

  • SUNY College at Oneonta, BS, Biology/Pre-Med, 2010
  • West Virginia University, PhD, Cancer Cell Biology, 2016


It is the intricate detail of cellular processes, which are remarkably achieved by billions of simple molecules attracting and repelling each other, that makes organisms so fascinating. The field of oncology provides a venue to combine my interest in cellular function with my desire to increase human well-being. Biomedical research is a vital part in improving treatments and increasing patient survival. Dr. Moses believes it is very important that researchers and clinicians work together to achieve what both strive for, increasing the understanding and survivorship of human diseases. During his undergraduate education, he gained insight into the basic biological processes in life. When Dr. Moses performed independent cancer research his final year of undergraduate education, he began to grasp the complexity of tumor biology. The eye opening moment has not left him to this day. Dr. Moses marvels in the dynamics of cancer cell biology and will dedicate his life to better understanding cancer. Although he has studied hematological malignancies intensively during his graduate research career, he is knowledgeable in solid malignancies as well as normal cellular development. The graduate education and research experience obtained at West Virginia University, under Dr. Laura Gibson’s mentoring, provided a strong background for his future scientific endeavors. Dr. Moses's research projects focused on tumor microenvironment interactions with leukemia cells and the resistance that is acquired. From this environment, he was well prepared for the caliber of research performed in Dr. Curt Civin’s Laboratory. Since joining the Civin Laboratory, he has continued his pursuit to better understand the complexity of pathobiological mechanisms in acute leukemias he has investigated novel therapies. In conjunction with data obtained from past laboratory members, Dr. Moses's research project has discovered synergism between a family of anti-malarial drugs, artemisinins, and BCL2 inhibitors, including venetoclax (ABT199). From investigating the mechanism of synergy between these two classes of drugs, he has gained new scientific skills including experimental assessment of protein half-life, surface and intracellular molecules by multi-color flow cytometry, high throughput cell growth inhibition, and treatment and imaging of luciferase expressing leukemia cells in mouse xenografts. Collaborative mentoring from Dr. Civin and the Civin lab’s strong team will continue to advance his knowledge, skills, and research career exponentially. Dr. Moses holds a competitive position in the NIH/NCI T32-funded Cancer Biology Training Program at the University of Maryland Greenebaum Comprehensive Cancer Center, in which he attends and actively participates in monthly Research in Progress seminars centered around fellow T32-funded recipients’ recent findings. To continue to improve his communication skills as well as broaden his cancer biology knowledge, he attends several continuing education/research series that University of Maryland orchestrates, especially the monthly Frontiers in Oncology lectures and the monthly fellows’ journal club, as well as seminars coordinated by the Stem Cell Center and School of Medicine. Improving scientific leadership and professional development is important in maturing as a scientist, and Dr. Moses has attended symposia and courses centered on these key attributes and plan to attend future courses when available.

Research/Clinical Keywords

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pre-clinical Drug Studies

Highlighted Publications

  1. Moses BS, Evans R, Slone WL, Piktel D, Martinez I, Craig MD, Gibson LF. Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia. Mol Cancer Res. 2016 Oct;14(10):909-919. PubMed PMID: 27358112; PubMed Central PMCID: PMC5065748.
  2. Slone WL, Moses BS, Hare I, Evans R, Piktel D, Gibson LF. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy. Oncotarget. 2016 Apr 26;7(17):23439-53. PubMed PMID: 27015556; PubMed Central PMCID: PMC5029638.
  3. Moses BS, Slone WL, Thomas P, Evans R, Piktel D, Angel PM, Walsh CM, Cantrell PS, Rellick SL, Martin KH, Simpkins JW, Gibson LF. Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype. Exp Hematol. 2016 Jan;44(1):50-9.e1-2. PubMed PMID: 26407636; PubMed Central PMCID: PMC4684957.
  4. Bruce A, Evans R, Mezan R, Shi L, Moses BS, Martin KH, Gibson LF, Yang Y. Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic Leukemia. PLoS One. 2015;10(10):e0140506. PubMed PMID: 26488876; PubMed Central PMCID: PMC4619215.

Additional Publication Citations

Awards and Affiliations

  • Dean’s List , SUNY College at Oneonta, 2006-2010
  • Provost's List, SUNY College at Oneonta, 2008-2010
  • Hans Wilk Scholarship , SUNY College at Oneonta, 2008-2010
  • Academic Achievement Award, SUNY College at Oneonta, 2010
  • Honors in Biology, SUNY College at Oneonta, 2010
  • All College Honors (Magna Cum Laude), SUNY College at Oneonta, 2010
  • Van Liere Convocation Poster Presentation- 1st Place, SUNY College at Oneonta, 2016
  • Cancer Biology Research Retreat Poster Presentation- 1st Place, University of Maryland SOM, 2016

Grants and Contracts

  • T32CA154274 NIH/NCI Cancer Biology Training Program at the University of Maryland Greenebaum Comprehensive Cancer Center, 2016-Present